Publications by authors named "R Komers"
Am J Kidney Dis
October 2024
Article Synopsis
- - Focal Segmental Glomerulosclerosis (FSGS) is a complex kidney disorder that leads to nephrotic syndrome and can cause kidney failure in both children and adults.
- - The Kidney Health Initiative is exploring the potential of using proteinuria (excess protein in urine) as a key indicator for measuring treatment outcomes in FSGS clinical trials.
- - While total remission of proteinuria seems to correlate strongly with better kidney health, more research is necessary to establish how to best evaluate treatment effects, with ongoing efforts to consolidate data from various studies.
JCI Insight
September 2024
Article Synopsis
- Sparsentan, a dual ET-1 and AngII receptor antagonist, shows stronger antiproteinuric effects than standard treatments like ARBs, highlighting its potential for better kidney protection.
- In studies on healthy and FSGS kidney models, sparsentan improved blood flow, increased glomerular filtration, and preserved essential kidney cells while reducing harmful calcium levels and proteinuria.
- Overall, sparsentan demonstrated significant benefits in kidney structure and function compared to losartan, emphasizing the critical role of ET-1 in treating FSGS.
Article Synopsis
- Sparsentan, a new dual endothelin angiotensin receptor antagonist, was evaluated in the ongoing phase 2 DUET trial for treating focal segmental glomerulosclerosis (FSGS) and showed a significant reduction in proteinuria over an 8-week period compared to irbesartan.
- The study involved 109 patients with FSGS and tracked their response to various doses of sparsentan (200, 400, and 800 mg/d) for up to 4.6 years, measuring urinary protein levels, glomerular filtration rate, and blood pressure at regular intervals.
- Results indicated that 52.8% of patients achieved partial remission within 9 months, which was linked to a
Clin Sci (Lond)
June 2024
Article Synopsis
- * Sparsentan is FDA-approved for treating immunoglobulin A nephropathy (IgAN) and is being studied for rare kidney diseases like focal segmental glomerulosclerosis.
- * Clinical studies show that sparsentan is effective and safe, with benefits including anti-inflammatory and antifibrotic actions in the kidney, suggesting its potential for treating various renal diseases.
